Share Prices & Company Research

Market News

26 Jan 2021 | 15:26

Regeneron Pharmaceuticals Covid-19 antibodies 100% effective in blocking infections

(Sharecast News) - Regeneron Pharmaceuticals antibody cocktail severely curtails Covid-19 symptoms and infections, the results of a late-stage trial showed.

The trial involving 400 patients with at least one household member sick from Covid-19 showed that the two-antibody cocktail, known as REGEN-COV, completely cut symptomatic infections of the novel coronavirus.

Overall rates of infections meanwhile were reduced by approximately half.

A rival treatment from Eli Lilly, bamlanivimab, had shown a similar efficacy the week before, reducing Covid-19 infections among nursing home resident in a trial by 80%.

As of 1650 GMT, Regeneron shares had slipped 1.11% to $542.14.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.